In the lab animals, supplements of lipoic acid lowered triglyceride levels up to 60 percent. If the effect were the same in humans – which is not yet clear – that would be a greater impact than found with other dietary supplements, and similar to the effects of some prescription drugs.
The results were just published in the Archives of Biochemistry and Biophysics, a professional journal.
"The extent of triglyceride reduction was really dramatic, we didn't expect it to be this profound," said Regis Moreau, an assistant professor with the Linus Pauling Institute at Oregon State University. "The potential is good that this could become another way to lower blood triglycerides and help reduce the risk of atherosclerosis. It's pretty exciting."
Lipoic acid is a natural compound found at low levels in some foods, including red meat and green leafy vegetables. A powerful antioxidant, it's been of considerable research interest in recent years for its apparent ability to reduce mitochondrial decay in cells and perhaps slow the process of aging. And it's been used in Europe for decades as a treatment for the neuropathic complications of diabetes.
"Lipoic acid is known to influence glucose uptake, and bring down blood glucose by increasing its transport into skeletal muscle," Moreau said. "Less has been done to study its potential value in reducing triglycerides."
Until about 10 years ago, Moreau said, high blood levels of triglycerides – basically a form of fat – were not thought to be as significant as cholesterol at predicting atherosclerosis and heart disease. That perspective has changed, he added, and most experts now see triglycerides as a third important risk factor for atherosclerosis, along with levels of "good" HDL and "bad" LDL cholesterol.
Widely prescribed medications are often taken to influence all of these issues, especially when efforts to control them with diet, exercise, and proper weight have not been effective. However, some of these medications have unwanted side effects that remain a concern.
In this research, it was found that supplements of lipoic acid appeared to affect triglyceride levels through two pathways. After eating, lipoic acid supplementation increased the rate of disappearance of triglycerides in the bloodstream. And supplements also reduced the genetic expression of enzymes in the liver that synthesize triglycerides.
This is the first study that has identified the molecular targets by which lipoic acid can lower triglyceride levels, the researchers said, and to show the effect on liver enzymes resulting in less production of triglycerides. It also found that the mechanism of action of how lipoic acid can lower triglycerides appears separate and distinct from that provided by fibrate drugs, a group of prescription medications often used for that purpose.
Lipoic acid supplements have in various studies been shown to be an appetite suppressant, but control groups of laboratory animals were used in this research to ensure that lower triglyceride levels were not the result simply of less food intake.
The rats used in the experiment were obese to begin with, and developed higher triglyceride levels as the experiment proceeded and they aged – but the animals given lipoic acid fared much better. As they grew from five weeks of age to nine weeks, the blood triglyceride levels doubled in rats given the supplement, but went up more than 400 percent in the other group not given supplements.
The amount of lipoic acid supplementation used in these laboratory experiments would equate to about two grams per day for a 150-pound person, researchers said. Lipoic acid has been used by some people for years as a dietary supplement and found to be safe, Moreau said.
Tory Hagen, a principal investigator and holder of the Jamieson Endowed Chair in Healthspan Research at the Linus Pauling Institute, was a co-author on this study. The work was supported by the National Institutes of Health and the National Center for Complementary and Alternative Medicine.
"We believe that a novel means of controlling triglyceridemia in this animal model has been revealed," researchers wrote in their report. "Given its strong safety record, lipoic acid may have therapeutic applications for the treatment or prevention of hypertriglyceridemia and diabetic dyslipidemia in humans."
Regis Moreau | EurekAlert!
Further reports about: > HDL > LDL > Lipoic acid > blood pressure > cardiovascular disease > cholesterol > cholesterol levels > diabetic dyslipidemia > dietary supplements > genetic expression of enzymes > lower blood triglycerides > prescription drugs > triglyceride levels > triglyceride reduction > triglyceridemia > triglycerides
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences